Suppr超能文献

新型吡咯衍生物的设计、合成及作为潜在结核分枝杆菌 ClpP1P2 抑制剂的生物评价。

Design, synthesis and biological evaluation of novel pyrrole derivatives as potential ClpP1P2 inhibitor against Mycobacterium tuberculosis.

机构信息

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.

State Key Laboratory of Respiratory Disease, Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China; Institute of Physical Science and Information Technology, Anhui University, Hefei 230601, China.

出版信息

Bioorg Chem. 2018 Oct;80:422-432. doi: 10.1016/j.bioorg.2018.06.004. Epub 2018 Jun 4.

Abstract

In an effort to discover novel inhibitors of M. tuberculosis Caseinolytic proteases (ClpP1P2), a combination strategy of virtual high-throughput screening and in vitro assay was employed and a new pyrrole compound, 1-(2-chloro-6-fluorobenzyl)-2, 5-dimethyl-4-((phenethylamino)methyl)-1H-pyrrole-3-carboxylate was found to display inhibitory effects against HRa with an MIC value of 77 µM. In order for discovery of more potent anti-tubercular agents that inhibit ClpP1P2 peptidase in M. tuberculosis, a series of pyrrole derivatives were designed and synthesized based on this hit compound. The synthesized compounds were evaluated forin vitrostudies against ClpP1P2 peptidase and anti-tubercular activities were also evaluated. The most promising compounds 2-(4-bromophenyl)-N-((1-(2-chloro-6-fluorophenyl)-2, 5-dimethyl-1H- pyrrolyl)methyl)ethan-1-aminehydrochloride 7d, ethyl 4-(((4-bromophenethyl) amino) methyl)-2,5-dimethyl-1-phenyl-1H-pyrrole-3-carboxylate hydrochloride 13i, ethyl 1-(4-chlorophenyl)-4-(((2-fluorophenethyl)amino)methyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate hydrochloride 13n exhibited favorable anti-mycobacterial activity with MIC value at 5 µM against Mtb HRa, respectively.

摘要

为了发现新型结核分枝杆菌天冬氨酸蛋白酶(ClpP1P2)抑制剂,采用虚拟高通量筛选和体外测定相结合的策略,发现了一种新的吡咯化合物 1-(2-氯-6-氟苄基)-2,5-二甲基-4-((苯乙胺基)甲基)-1H-吡咯-3-羧酸乙酯对 HRa 具有抑制作用,MIC 值为 77µM。为了发现更多能够抑制结核分枝杆菌 ClpP1P2 肽酶的有效抗结核药物,基于该命中化合物设计并合成了一系列吡咯衍生物。对合成化合物进行了体外 ClpP1P2 肽酶抑制活性评价,并对其抗结核活性进行了评价。最有前景的化合物 2-(4-溴苯基)-N-((1-(2-氯-6-氟苯基)-2,5-二甲基-1H-吡咯基)甲基)乙-1-胺盐酸盐 7d、4-(((4-溴苯乙基)氨基)甲基)-2,5-二甲基-1-苯基-1H-吡咯-3-羧酸乙酯盐酸盐 13i、1-(4-氯苯基)-4-(((2-氟苯乙基)氨基)甲基)-2-甲基-5-苯基-1H-吡咯-3-羧酸乙酯盐酸盐 13n 对 Mtb HRa 的 MIC 值分别为 5µM,表现出良好的抗分枝杆菌活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验